Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
News|Articles|September 1, 2026
What Every Oncology Pharmacist Should Know About Gynecologic Cancer This September
Fact checked by: Kirsty Mackay
This FAQ describes what oncology pharmacists should know ahead of Gynecologic Cancer Awareness Month in September.
Advertisement
Advertisement
September is Gynecologic Cancer Awareness Month, an annual observance promoted by the Foundation for Women’s Cancer and the Society of Gynecologic Oncology to raise awareness of the 5 gynecologic cancers: cervical, ovarian, uterine, vaginal, and vulvar.1 An estimated 112,000 women will be diagnosed with a gynecologic cancer in the US in 2026, and approximately 32,680 will die from one.2,3
Related to this article
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Advertisement
Advertisement